© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Converge Coverage
Uptake of new heart failure drugs slow despite guidelines
EXPERT ANALYSIS FROM THE CARDIOVASCULAR CONFERENCE AT SNOWMASS
Related Articles
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
April 5, 2017
Clinical question: Are there alternatives to statins for primary prevention? Background: Statins that lower low-density lipoprotein (LDL) cholesterol are major therapeutics in reducing both primary...
Beta-Blocker Interruption or Continuation after Myocardial Infarction
April 5, 2017
Clinical question: Is the interrupted use of a beta-blocker non-inferior to its continued use in patients with a history of myocardial infarction (MI)? Background: Patients with MI are often started...
Can Salt Stir the Pot? Sodium’s Effect on Heart Failure Clinical Outcomes
April 5, 2017
Clinical question: Is there an association between baseline dietary sodium intake and clinical outcomes in heart failure? Background: Dietary sodium restriction is common advice for patients with...
Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients with Cirrhosis and AF
April 5, 2017
Clinical question: What is the effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation? Background: The use of direct oral anticoagulants...